COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA)

• Autor(es): Pagano, L ; Salmanton-García, J ; Marchesi, F ; Busca, A ; Corradini, P ; Hoenigl, M ; Klimko, N ; Koehler, P ; Pagliuca, A ; Passamonti, F ; Verga, L ; Víšek, B ; Ilhan, O ; Nadali, G ; Weinbergerová, B ; Córdoba-Mascuñano, R ; Marchetti, M ; Collins, GP ; Farina, F ; Cattaneo, C ; Cabirta, A ; Gomes-Silva, M ; Itri, F ; van Doesum, J ; Ledoux, MP ; Cernan, M ; Jakšic, O ; Duarte, RF ; Magliano, G ; Omrani, AS ; Fracchiolla, NS ; Kulasekararaj, A ; Valkovic, T ; Poulsen, CB ; Machado, M ; Glenthøj, A ; Stoma, I ; Rácil, Z ; Piukovics, K ; Navrátil, M ; Emarah, Z ; Sili, U ; Maertens, J ; Blennow, O ; Bergantim, R ; García-Vidal, C ; Prezioso, L ; Guidetti, A ; del Principe, MI ; Popova, M ; de Jonge, N ; Ormazabal-Vélez, I ; Fernández, N ; Falces-Romero, I ; Cuccaro, A ; Meers, S ; Buquicchio, C ; Antic, D ; Al-Khabori, M ; García-Sanz, R ; Biernat, MM ; Tisi, MC ; Sal, E ; Rahimli, L ; Colovic, N ; Schönlein, M ; Calbacho, M ; Tascini, C ; Miranda-Castillo, C ; Khanna, N ; Méndez, GA ; Petzer, V ; Novák, J ; Besson, C ; Duléry, R ; Lamure, S ; Nucci, M ; Zambrotta, G ; Žák, P ; Seval, GC ; Bonuomo, V ; Mayer, J ; López-García, A ; Sacchi, MV ; Booth, S ; Ciceri, F ; Oberti, M ; Salvini, M ; Izuzquiza, M ; Nunes-Rodrigues, R ; Ammatuna, E ; Obr, A ; Herbrecht, R ; Núñez-Martín-Buitrago, L ; Mancini, V ; Shwaylia, H ; Sciumè, M ; Essame, J ; Nygaard, M ; Batinic, J ; Gonzaga, Y ; Regalado-Artamendi, I ; Karlsson, LK ; Shapetska, M ; Hanakova, M ; El-Ashwah, S ; Borbényi, Z ; Çolak, GM ; Nordlander, A ; Dragonetti, G ; Maraglino, AME ; Rinaldi, A ; De Ramón-Sánchez, C ; Cornely, OA ; Finizio, O ; Fazzi, R ; Sapienza, G ; Chauchet, A ; Van Praet, J ; Prattes, J ; Dargenio, M ; Rossi, C ; Shirinova, A ; Malak, S ; Tafuri, A ; Ommen, HB ; Bologna, S ; Khedr, RA ; Choquet, S ; Joly, B ; Ceesay, MM ; Philippe, L ; Kho, CS ; Desole, M ; Tsirigotis, P ; Otaševic, V ; Borducchi, DMM ; Antoniadou, A ; Gaziev, J ; Almaslamani, MA ; García-Poutón, N ; Paterno, G ; Torres-López, A ; Tarantini, G ; Mellinghoff, S ; Gräfe, S ; Börschel, N ; Passweg, J ; Merelli, M ; Barac, A ; Wolf, D ; Shaikh, MU ; Thiéblemont, C ; Bernard, S ; Funke, VAM ; Daguindau, E ; Khostelidi, S ; Nucci, FM ; Martín-González, JA ; Landau, M ; Soussain, C ; Laureana, C ; Lacombe, K ; Kohn, M ; Aliyeva, G ; Piedimonte, M ; Fouquet, G ; Rêgo, M ; Hoell-Neugebauer, B ; Cartron, G ; Pinto, F ; Alburquerque, AM ; Passos, J ; Yilmaz, AF ; Redondo-Izal, AM ; Altuntas, F ; Heath, C ; Kolditz, M ; Schalk, E ; Guolo, F ; Karthaus, M ; Della Pepa, R ; Vinh, D ; Noël, N ; Deau Fischer, B ; Drenou, B ; Mitra, ME ; Meletiadis, J ; Bilgin, YM ; Jindra, P ; Espigado, I ; Drgona, L ; Serris, A ; Di Blasi, R ; Ali, N
• Data: 2021
• Identificador Persistente: https://hdl.handle.net/10216/154867
• Origem: Repositório Aberto da Universidade do Porto
• Assunto(s): COVID-19; EHA; Epidemiology; Hematological malignancies; Pandemic
• Tipo de Documento: Artigo científico
• Idioma: Inglês

Descrição

Background: Patients with hematological malignancies (HM) are at high risk of mortality from SARS-CoV-2 disease 2019 (COVID-19). A better understanding of risk factors for adverse outcomes may improve clinical management in these patients. We therefore studied baseline characteristics of HM patients developing COVID-19 and analyzed predictors of mortality. Methods: The survey was supported by the Scientific Working Group Infection in Hematology of the European Hematology Association (EHA). Eligible for the analysis were adult patients with HM and laboratory-confirmed COVID-19 observed between March and December 2020. Results: The study sample includes 3801 cases, represented by lymphoproliferative (mainly non-Hodgkin lymphoma n = 1084, myeloma n = 684 and chronic lymphoid leukemia n = 474) and myeloproliferative malignancies (mainly acute myeloid leukemia n = 497 and myelodysplastic syndromes n = 279). Severe/critical COVID-19 was observed in 63.8% of patients (n = 2425). Overall, 2778 (73.1%) of the patients were hospitalized, 689 (18.1%) of whom were admitted to intensive care units (ICUs). Overall, 1185 patients (31.2%) died. The primary cause of death was COVID-19 in 688 patients (58.1%), HM in 173 patients (14.6%), and a combination of both COVID-19 and progressing HM in 155 patients (13.1%). Highest mortality was observed in acute myeloid leukemia (199/497, 40%) and myelodysplastic syndromes (118/279, 42.3%). The mortality rate significantly decreased between the first COVID-19 wave (March–May 2020) and the second wave (October–December 2020) (581/1427, 40.7% vs. 439/1773, 24.8%, p value < 0.0001). In the multivariable analysis, age, active malignancy, chronic cardiac disease, liver disease, renal impairment, smoking history, and ICU stay correlated with mortality. Acute myeloid leukemia was a higher mortality risk than lymphoproliferative diseases. Conclusions: This survey confirms that COVID-19 patients with HM are at high risk of lethal complications. However, improved COVID-19 prevention has reduced mortality despite an increase in the number of reported cases.